Maráz, Anikó <br/><br/>
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.  [electronic resource] 

 -  BMC cancer  03 2018 
 - 296 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-018-4209-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Nephrectomy<br/>Pyrroles--administration & dosage<br/>Sunitinib<br/>Treatment Outcome